New dosing strategies for liposomal amphotericin B in high-risk patients

Clinical Microbiology and Infection

Volumn 14, Issue SUPPL. 4, 2008, Pages 55-64

  Ellis, Michael ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

CAB; Intermittent dosing; LAB; Review; Tissue concentrations

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; PLACEBO; PYRROLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ASPERGILLOSIS; CHILL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG RESPONSE; DRUG RETENTION; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; DYSPNEA; FEBRILE NEUTROPENIA; HIGH RISK PATIENT; HOST RESISTANCE; HUMAN; HYPOTENSION; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; INFECTION RISK; LIVER TOXICITY; LOADING DRUG DOSE; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RIGOR; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL RATE; SYSTEMIC MYCOSIS; THORAX PAIN; TISSUE DISTRIBUTION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANIMALIA; FUNGI;

EID: 42649106153     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2008.01982.x     Document Type: Review

References (39)

1. TJ Walsh H Teppler GR Donowitz Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia N Engl J Med 351 2004 1391 1402
2. JE Bennett J Powers T Walsh Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients Clin Infect Dis 36 2003 S117 S122
3. TJ Walsh RW Finberg C Arndt Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group N Engl J Med 340 1999 764 771
4. DW Bates L Su DT Yu Mortality and costs of acute renal failure associated with amphotericin B therapy Clin Infect Dis 32 2001 686 693
5. L Ostrosky-Zeichner KA Marr JH Rex SH Cohen Amphotericin B: time for a new ‘gold standard’ Clin Infect Dis 37 2003 415 425
6. JR Wingard MH White E Anaissie A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group Clin Infect Dis 31 2000 1155 1163
7. PA Pizzo KJ Robichaud FA Gill FG Witebsky Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia Am J Med 72 1982 101 111
8. EORTC International Antimicrobial Therapy Cooperative Group Empiric antifungal therapy in febrile granulocytopenic patients Am J Med 86 1989 668 672
9. BE de Pauw Between over- and undertreatment of invasive fungal disease Clin Infect Dis 41 2005 1251 1253
10. CD Pfeiffer JP Fine N Safdar Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis Clin Infect Dis 42 2006 1417 1427
11. JH Rex Galactomannan and the diagnosis of invasive aspergillosis Clin Infect Dis 42 2006 1428 1430
12. J Maertens K Theunissen G Verhoef Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study Clin Infect Dis 41 2005 1242 1250
13. L Ostrosky-Zeichner BD Alexander DH Kett Multicenter clinical evaluation of the (1–3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans Clin Infect Dis 41 2005 654 659
14. Z Odabasi G Mattiuzzi E Estey Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome Clin Infect Dis 39 2004 199 205
15. A Hauggaard M Ellis L Ekelund Early chest radiography and CT in the diagnosis, management and outcome of invasive pulmonary aspergillosis Acta Radiol 43 2002 292 298
16. JP Adler-Moore RT Proffitt Development, characterization, efficacy and mode of action of AmBisome, a unilamellar formulation of amphotericin B J Liposome Res 3 1993 429 450
17. KM Wasan G Lopez-Berestein Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients Clin Infect Dis 23 1996 1126 1138
18. J Adler-Moore AmBisome targeting to fungal infections Bone Marrow Transplant 14 1994 S3 S7
19. TJ Walsh JL Goodman P Pappas Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study Antimicrob Agents Chemother 45 2001 3487 3496
20. JA Olson JP Adler-Moore PJ Smith RT Proffitt Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin Antimicrob Agents Chemother 49 2005 4895 4902
21. JA Olson JP Adler-Moore J Schwartz GM Jensen RT Proffitt Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model Antimicrob Agents Chemother 50 2006 2122 2131
22. NP Wiederhold VH Tam J Chi RA Prince DP Kontoyiannis RE Lewis Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis Antimicrob Agents Chemother 50 2006 469 473
23. D Andes N Safdar K Marchillo R Conklin Pharmacokinetic–pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models Antimicrob Agents Chemother 50 2006 674 684
24. OA Comely J Maertens M Bresnik Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial) Clin Infect Dis 44 2007 1289 1297
25. PJ Smith JA Olson D Constable J Schwartz RT Proffitt JP Adler-Moore Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B J Antimicrob Chemother 59 2007 941 951
26. H Vogelsinger S Weiler A Djanani Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion J Antimicrob Chemother 57 2006 1153 1160
27. G Demartini C Lequaglie PP Brega Massone F Scaglione F Fraschini Penetration of amphotericin B in human lung tissue after single liposomal amphotericin B (AmBisome) infusion J Chemother 17 2005 82 85
28. O Ringdén F Meunier J Tollemar Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients J Antimicrob Chemother 28 1991 73 82
29. N Collette P van der Auwera AP Lopez C Heymans F Meunier Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate Antimicrob Agents Chemother 33 1989 362 368
30. JP Gangneux A Sulahian YJ Garin R Farinotti F Derouin Therapy of visceral leishmaniasis due to Leishmania infantum : experimental assessment of efficacy of AmBisome Antimicrob Agents Chemother 40 1996 1214 1218
31. AH Groll CA Lyman V Petraitis Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations Antimicrob Agents Chemother 50 2006 3418 3423
32. J Adler-Moore RT Proffitt Effect of tissue penetration on AmBisome efficacy Curr Opin Investig Drugs 4 2003 179 185
33. A Garcia JP Adler-Moore RT Proffitt Single-dose AmBisome (liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis Antimicrob Agents Chemother 44 2000 2327 2332
34. JP Adler-Moore JA Olson RT Proffitt Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis J Antimicrob Chemother 54 2004 1096 1102
35. J El-Cheikh C Faucher S Fürst High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation Bone Marrow Transplant 39 2007 301 306
36. P Mehta A Vinks A Filipovich High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study Biol Blood Marrow Transplant 12 2006 235 240
37. C Cordonnier M Mohty C Faucher Safety of a weekly administration of 10 mg/kg of liposomal amphotericin B for antifungal prophylaxis in allogeneic stem-cell transplant and acute leukemia patients Blood 106 2005 Abstract 5346 (ASH Annual Meeting Abstracts).
38. SM Kelsey JM Goldman S McCann Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study Bone Marrow Transplant 23 1999 163 168
39. O Penack S Schwartz P Martus Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial Ann Oncol 17 2006 1306 1312